Latest Maraviroc Stories
- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...
Patients taking Selzentry, in combination with Combivir(R) (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES (Reanalysis of the MERIT Study with the Enhanced Trofile Assay) reanalysis presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC(TM))/ 46th Annual Meeting of the Infectious Diseases Society...
SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that Wellpoint, Inc. has established a national Medical Policy Guideline for Monogram's Trofile Assay.
SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain.
GlaxoSmithKline Plc has suffered a setback in the race to develop a new kind of AIDS pill, following two cases of serious liver problems in patients taking its experimental drug aplaviroc.
- A mania for the use of printing-types; a strong propensity to write for publication.